Goria, Odile

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: Interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Younossi, Z. M., Ratziu, V., Loomba, R., Rinella, M., Anstee, Q. M., Goodman, Z., Bedossa, P., Geier, A., Beckebaum, S., Newsome, P. N., et al. (2019) · The Lancet

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 1,277

A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis

Corpechot, C., Chazouillères, O., Rousseau, A., Le Gruyer, A., Habersetzer, F., Mathurin, P., Goria, O., Potier, P., Minello, A., Silvain, C., et al. (2018) · New England Journal of Medicine

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 642

A 2-year multicenter, double-blind, randomized, placebo-controlled study of bezafibrate for the treatment of primary biliary cholangitis in patients with inadequate biochemical response to ursodeoxycholic acid therapy (Bezurso)

Corpechot, C., Chazouillères, O., Rousseau, A., Guyader, D., Habersetzer, F., Mathurin, P., Goria, O., Potier, P., Minello, A., Silvain, C., et al. (2017) · Journal of Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 45